Humana Inc. (HUM) Stock Analysis
Healthcare · Healthcare Plans · NYSE
Humana Inc. (HUM) posted $129.66B in revenue for fiscal 2025 (up 10.1% year over year), at a 0.9% net margin, and has compounded revenue about 10.9%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Humana Inc.
Humana Inc. has grown revenue from $54.38B to $129.66B over the last 10 fiscal years, compounding about 10.9% a year. The most recent year was up 10.1%, roughly in line with its longer-run pace.
Net margin sits at 0.9%. It carries about $12.37B of total debt.
At today's valuation the market is pricing in roughly 32.1% annual free-cash-flow growth — versus the -39.6% it actually delivered over the last five years, so the price already assumes a step-up from the recent record. The one thing worth a second look in the filings is heavy debt load.
Synthesised from Humana Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Humana Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.38B | $53.77B | $56.91B | $64.89B | $77.16B | $83.06B | $92.87B | $106.37B | $117.76B | $129.66B |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $614.00M | $2.45B | $1.68B | $2.71B | $3.37B | $2.93B | $2.81B | $2.49B | $1.21B | $1.19B |
| Net margin | 1.1% | 4.6% | 3.0% | 4.2% | 4.4% | 3.5% | 3.0% | 2.3% | 1.0% | 0.9% |
Source: Humana Inc. SEC filings (10-K). 19 years of history available in the interactive view.
Humana Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Heavy debt loadTotal debt of $12369M is 13.4× last year's operating cash flow — it would take years of cash flow to clear.
What growth is priced into HUM stock?
At today's market cap of $43.69B, Humana Inc. is priced for free-cash-flow growth of about 32.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $375.00M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -39.6%/yr over the last five fiscal years and revenue 10.9%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Humana Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track HUM in your portfolio →
Humana Inc. financial history by metric
Compare Humana Inc. with peers
About Humana Inc.
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Humana Inc. — frequently asked questions
What is Humana Inc.'s revenue?
Humana Inc. (HUM) reported revenue of $129.66B for fiscal year 2025, up 10.1% from the prior year, according to its SEC filings.
Is Humana Inc. profitable?
Yes. HUM earned net income of $1.19B in fiscal 2025, a net margin of 0.9%.
What is HUM's P/E ratio?
Humana Inc. trades at a price-to-earnings ratio of about 34.4 based on the latest data in our nightly-refreshed cache.
How fast is Humana Inc. growing?
HUM's revenue grew at roughly 10.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Humana Inc. have?
As of fiscal year 2025, HUM carried roughly $12.37B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Humana Inc.'s market cap?
Humana Inc. (HUM) has a market capitalization of about $43.69B, based on the latest data in our nightly-refreshed cache.
When does Humana Inc.'s fiscal year end?
HUM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into HUM stock?
At today's market cap of $43.69B, Humana Inc. is priced for free-cash-flow growth of about 32.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $375.00M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -39.6%/yr over the last five fiscal years and revenue 10.9%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Humana Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.